Acquisitions (Details) - USD ($)		1 Months Ended	3 Months Ended	6 Months Ended
	Jul. 13, 2023	Apr. 19, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Acquisitions (Details) [Line Items]
Consideration amount		$ 20,000,000
Business acquisition, description				(i) $6.0 million paid upon the closing of the Transaction on April 19, 2023, (ii) an additional $4.0 million in the form of a non-interest bearing note payable due on September 30, 2023, and (iii) an additional $10.0 million in the form of two $5.0 million non-interest bearing notes payable, each due on April 19, 2024 and September 30, 2024.
Net sales amount		$ 80,000,000
Royalty sales percentage		6.00%
Sales payments amount		$ 22,500,000
Business transaction years		5 years
Estimated useful life		5 years
Inventory fair value		$ 300,000
Cash payment amount	$ 4,500,000
Initial payment amount	3,500,000
Company payments	3,500,000
Payment as deposit	3,500,000
Cash target amount	$ 1,100,000
Initial payment				$ 3,500,000	$ 63,000
Loss on impairment			$ 3,500,000	$ 3,500,000
ENTADFI [Member]
Acquisitions (Details) [Line Items]
Description of company achievement				(i) $10.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $100.0 million during a calendar year, (ii) $20.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $200.0 million during a calendar year, and (3) $50.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $500.0 million during a calendar year.
Estimated using discount percentage		8.20%
Asset Purchase Agreement [Member]
Acquisitions (Details) [Line Items]
Consideration amount		$ 100,000,000
Pharmaceutical Services, LLC [Member] | ENTADFI [Member]
Acquisitions (Details) [Line Items]
Business acquisition, description				(i) $5.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $100.0 million during a calendar year, (ii) $7.5 million is payable upon the first time the Company achieves net sales from ENTADFI® of $200.0 million during a calendar year, and (3) $10.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $300.0 million during a calendar year.
WraSer APA [MEmber]
Acquisitions (Details) [Line Items]
Business acquisition, description				(i) $3.5 million in cash at signing of the WraSer APA; (ii) $4.5 million in cash on the later of (x) 90 days after the signing of the WraSer APA or (y) the date that all closing conditions under the WraSer APA are met or otherwise waived (the “Closing Date”); (iii) 1.0 million shares of the Company’s common stock (the “Closing Shares”) issuable on the Closing Date, and (iv) $500,000 in cash one year from the Closing Date.